Skip to main content

16.03.2016 | Original Article | Ausgabe 4/2016 Open Access

Cancer Chemotherapy and Pharmacology 4/2016

A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers

Cancer Chemotherapy and Pharmacology > Ausgabe 4/2016
Beverly Knight, Danielle Rassam, Shanmei Liao, Reginald Ewesuedo
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1007/​s00280-016-3001-2) contains supplementary material, which is available to authorized users.



This study compared the pharmacokinetics of PF-06439535, a potential bevacizumab biosimilar, to bevacizumab sourced from the European Union (bevacizumab-EU) and USA (bevacizumab-US), and of bevacizumab-EU to bevacizumab-US.


In this double-blind study, 102 healthy males, aged 21–55 years, were randomized 1:1:1 to receive a single 5 mg/kg intravenous dose of PF-06439535, bevacizumab-EU, or bevacizumab-US. Pharmacokinetic assessments were conducted for 71 days, with additional safety and immunogenicity assessments until day 100. Pharmacokinetic similarity was achieved if 90 % confidence intervals (CIs) for the test-to-reference ratios of the maximum serum concentration (C max), area under the serum concentration–time curve from zero to infinity (AUC0–∞), and from zero to time of last quantifiable concentration (AUC0–t ) were within the 80.00–125.00 % bioequivalence acceptance window.


The three study drugs exhibited similar pharmacokinetic properties. For the comparisons of PF-06439535 to bevacizumab-EU or bevacizumab-US, and of bevacizumab-EU to bevacizumab-US, the 90 % CIs for the ratios of C max, AUC0–t , and AUC0–∞ were all within 80.00–125.00 %. Two, one, and two subjects treated with PF-06439535, bevacizumab-EU, and bevacizumab-US, respectively, tested positive for antidrug antibodies, none of whom tested positive for neutralizing antibodies. Treatment-related adverse events were reported in 15.2, 25.7, and 18.2 % of subjects in the PF-06439535, bevacizumab-EU, and bevacizumab-US treatment arms, respectively.


This study demonstrated the pharmacokinetic similarity of PF-06439535 to both bevacizumab-EU and bevacizumab-US, and of bevacizumab-EU to bevacizumab-US. The safety profile (including immunogenicity) was similar in the three treatment groups, with no significant safety findings reported.

Unsere Produktempfehlungen

e.Med Interdisziplinär


Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

e.Med Innere Medizin


Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

e.Med Onkologie


Mit e.Med Onkologie erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Onkologie, den Premium-Inhalten der onkologischen Fachzeitschriften, inklusive einer gedruckten onkologischen Zeitschrift Ihrer Wahl.

Fig. S1 Study design. a Hours at which samples were collected for ADA. Samples for PK were collected at all times shown. ADA antidrug antibody; AE adverse event, PK pharmacokinetics. (EPS 1968 kb)
Fig. S2 Individual and geometric mean C max, AUC0-t , and AUC0-∞ for PF-06439535, bevacizumab-EU, and bevacizumab-US. (a) C max; (b) AUC0-t ; and (c) AUC0-∞ . Stars (★) represent geometric mean and circles (o) represent individual subject values. Box plot provides median and 25 %/75 % quartiles with whiskers to the last point within 1.5 × inter-quartile range. AUC 0-∞ area under the serum concentration-time profile from zero extrapolated to infinite time; AUC 0-t area under the serum concentration-time profile from zero to the time of the last quantifiable concentration; C max maximum observed serum concentration. (EPS 2415 kb)
Über diesen Artikel

Weitere Artikel der Ausgabe 4/2016

Cancer Chemotherapy and Pharmacology 4/2016 Zur Ausgabe

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.